Results 91 to 100 of about 229,492 (119)

Graves' ophthalmopathy

Swiss Medical Weekly, 2002
Swiss Medical Weekly
doaj   +1 more source

Rapid Publication Retrobulbar T Cells from Patients with Graves' Ophthalmopathy Are CD8+ and Specifically Recognize Autologous Fibroblasts

, 2020
Graves' ophthalmopathy is an autoimmune condition characterized by T cell infiltration of the retrobulbar ...
K Trieb, A Sztankay, H Anderl, G Wick, W Holter, B Grubeck-Loebenstein   +5 more
core  

Plasma exchange therapy for severe graves' ophthalmopathy

, 1986
In the present studies, the authors report on the treatment of nine Graves' disease patients with severe ophthalmopathy by use of intensive plasma exchange followed by immunosuppression (during three to six months). Results of treatment were evaluated by
Winand, René, Schrooyen, Marc, Glinoer, Daniel   +2 more
core   +1 more source

Steroid Treatment Focused Management of Graves’ Ophthalmopathy

Acta Medica Bulgarica
Graves' disease (GD) is an autoimmune disease that affects the thyroid and the eyes. Graves' ophthalmopathy (GO), an autoimmune disease, usually appears 18 months after GD diagnosis.
Condeng Y. H., Umar H., Aman A. M., Rasyid H., Bakri S., Iskandar H.   +5 more
doaj   +1 more source

Urinary glycosaminoglycan levels in patients with Graves' opthalmopathy: An effective parameter for the grading of ophthalmopathy

, 1996
An increased accumulation of glycosaminoglycans (GAGs) in retrobulbar tissues has been reported in patients with Graves' ophthalmopathy (GO). We examined quantitative urinary GAGs excretion in patients with different grades of GO. 36 patients with Graves'
Ademoglu, Evin, Gokkusu, CAHİDE, Yarman, S, Turkoglu, UM, Alagol, F   +4 more
core  

Graves\u27 Ophthalmopathy Following HTLV-I Infection

, 2013
After years of diagnosing and following hundreds of patients with Graves\u27 Ophthalmopathy we discovered a young woman who became ill with it within 4 months of converting to a positive HTLV-I antibody titer in routine Blood Bank screening (as a ...
Susan C. Benes
core  

Antioxidant agents in the treatment of Graves' ophthalmopathy

, 2000
PURPOSE: To report the effect of antioxidant agents in the treatment of mild and moderately severe Graves' ophthalmopathy. METHODS: Prospective, nonrandomized, comparative study performed at a referral center.
Bouzas, E.A., Koutras, D.A., Mastorakos, G., Karadimas, P.   +3 more
core   +1 more source

Orbital Manometry Safely Reveals Higher Orbital Tissue Tension and Lower Orbital Compartment Compliance in Graves Ophthalmopathy vs. Normal Patients

, 1998
We compared orbital tissue tension and orbital compartment compliance in normal vs Graves\u27 ophthalmopathy ...
Gregory Kosmorsky, DO; C. D. Riemann; J. A. Foster
core  

[Biological treatment options for Graves' ophthalmopathy]

, 2008
The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and ...
El Fassi, Daniel, Hegedüs, Laszlo, Nielsen, Claus Henrik   +2 more
core  

MHC Class II Region, CTLA4 Gene, and Ophthalmopathy in Patients With Graves' Disease

Lancet, The, 2001
Up to half of patients with Graves' hyperthyroidism have signs of thyroid associated ophthalmopathy, but the factors that cause this disorder are unknown.
J A Franklyn, J M Heward, S C L Gough
exaly   +2 more sources